skip to Main Content

Roche release new data on infants, children and adults

  • 13 June 2020

Roche have released new data which shows that Risdiplam significantly improves motor function after 24 months in people between the ages of 2 and 25 years, this includes both type 2 and type 3 patients. In addition the data also shows that after 12 months of patients previously treated he continues to show a rapid and sustained increase in SMN protein levels.

Read More
Back To Top